SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Bio Technology General - BTGC
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Jim Oravetz who wrote (1980)2/2/2000 1:02:00 PM
From: Jim Oravetz  Read Replies (1) of 2028
 
Draxis Health Starts Phase III Fibrimage Trials
MISSISSAUGA, Ont. -- Draxis Health Inc. (DRAX) said its Draximage Inc. radiopharmaceutical subsidiary has started Phase III clinical trials in Canada for Fibrimage, a diagnostic tool for deep vein thrombosis, or DVT.
In a news release, the drug company said the trial should involve 130 patients and be completed by the end of the year.
DVTs are blood clots that form in the lower limbs and can lead to a pulmonary embolism, or a blockage of blood flow to the lungs, a condition that kills about 200,000 people a year in the U.S., it said.
It said Fibrimage is based on Fibrin Binding Domain, a recombinant polypeptide developed by Bio-Technology General Corp. (BTGC) and licensed to Draximage on an exclusive, worldwide basis.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News